Ann: Mesoblast Update on Chronic Low Back Pain Program, page-161

Todays announcement was not really something which was not new news. In early June this was reported

"There is a significant need for a safe, efficacious, and durable opioid-sparing treatment in patients with chronic low back pain due to severely inflamed degenerative disc disease. Mesoblast intends to meet with FDA to discuss a potential pathway for approval of rexlemestrocel-L in patients with chronic discogenic lower back pain based on the observed durable reduction in pain and opioid sparing activity in the CLBP trial. "

And today this was announced:

"Mesoblast has filed a request and expects to hold a Type C meeting with the US Food & Drug Administration (FDA) during the current quarter to discuss the pathway to US regulatory approval for rexlemestrocel-L following the recently completed 404 patient Phase 3 trial in patients with chronic inflammatory back pain due to degenerative disc disease."

The meeting with the FDA is scheduled this quarter, hence we have until end September to know the outcome. It certainly is another opportunity for the shorts to do a "roller coaster" with the price and today's announcement has not done anything much to the price which gives traders the opportunity to capitalise on the ups and downs.

Just my thoughts.